TrialSignal
Clinical trial intelligence report
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for The Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-stimulating Agents
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 13, 2026
NCT ID
NCT05082584
Status
WITHDRAWN
Phase
Phase 3
Sponsor
Akebia Therapeutics
Executive brief
Investment-Ready Snapshot
The clinical trial aimed to evaluate the safety and efficacy of once-daily oral vadadustat for treating pediatric participants with anemia of chronic kidney disease who are naive to erythropoiesis-stimulating agents. The study was sponsored by Akebia Therapeutics and was intended to enroll participants aged 4 months to 16 years.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT05082584
Indication
Anemia of Chronic Kidney Disease
Modality
small molecule
Target
Anemia of Chronic Kidney Disease in Pediatric Patients
Intervention
Vadadustat
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.